Craft

Adaptimmune

Stock Price

$1.2

2024-05-01

Market Capitalization

$309.2 M

2024-05-01

Revenue

$60.3 M

FY, 2023

Adaptimmune Summary

Company Summary

Overview
Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.
Type
Public
Status
Active
Founded
2008
HQ
Philadelphia, PA, US | view all locations
Website
http://adaptimmune.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • David M. Mott

    David M. Mott, Chairman

    • Gavin Wood

      Gavin Wood, Chief Financial Officer

      • Lawrence M. Alleva

        Lawrence M. Alleva, Non-Executive Director

        • Ali Behbahani

          Ali Behbahani, Non-Executive Director

          Operating MetricsView all

          Patents Issued

          173

          FY, 2016

          Patent Applications

          69

          FY, 2016

          LocationsView all

          4 locations detected

          • Philadelphia, PA HQ

            United States

            351 Rouse Blvd

          • Milton, England

            United Kingdom

            101 Park Dr

          • Milton, England

            United Kingdom

            60 Jubilee Ave

          • Stevenage, England

            United Kingdom

            Gunnels Wood Rd

          Adaptimmune Financials

          Summary Financials

          Revenue (FY, 2023)
          $60.3M
          Net income (FY, 2023)
          ($113.9M)
          Cash (FY, 2023)
          $144.0M
          EBIT (FY, 2023)
          ($139.7M)

          Footer menu